Dupilumab for treatment of severe atopic dermatitis accompanied by lichenoid amyloidosis in adults: Two case reports

Figure 1 Skin lesions at various follow-up time points of patient 1 after the application of dupilumab to the lesions. A: Skin lesions on the back before the treatment of dupilumab; B: Skin lesions on both lower limbs before the treatment of dupilumab; C: Posterior trunk at 16-wk follow-up; D: Back at 55-wk follow-up; E: Skin lesions on both lower limbs at 55-wk follow-up.

Figure 2 Skin lesions at various follow-up time points of patient 2 after application of dupilumab to the lesions. A: Skin lesions of hands before the treatment of dupilumab; B: Skin lesions of both lower limbs before the treatment of dupilumab; C: 16-wk follow-up; D: 16-wk follow-up; E: Hands 1.5 year post-treatment follow-up; F: Lower limbs 1.5 years post-treatment follow-up.

Figure 3 Skin histopathology. A: Amorphous amyloid lump deposition with mild eosinophilic staining in the dermal papillary layer, consistent with amyloidosis (hematoxylin-eosin staining, 100 ×); B: Amorphous amyloid lump deposition with mild eosinophilic staining in the dermal papillary layer, consistent with amyloidosis (hematoxylin-eosin staining, 400 ×).